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In Alzheimer disease amyloid- (A) peptides derived from
the amyloid precursor protein (APP) accumulate in the brain.
Cleavage of APP by the -secretase BACE1 is the rate-limiting
step in the production of A. We have reported previously that
the cellular prion protein (PrPC) inhibited the action of BACE1
toward human wild type APP (APPWT) in cellular models and
that the levels of endogenous murine A were significantly
increased in PrPC-null mouse brain. Here we investigated the
molecular and cellularmechanismsunderlying this observation.
PrPC interacted directly with the prodomain of the immature
Golgi-localized form of BACE1. This interaction decreased
BACE1 at the cell surface and in endosomes where it preferen-
tially cleaves APPWT but increased it in the Golgi where it
preferentially cleaves APP with the Swedish mutation
(APPSwe). In transgenic mice expressing human APP
with the Swedish and Indiana familial mutations
(APPSwe,Ind), PrPC deletion had no influence on APP proteo-
lytic processing, Aplaque deposition, or levels of solubleA or
A oligomers. In cells, although PrPC inhibited the action of
BACE1 on APPWT, it did not inhibit BACE1 activity toward
APPSwe. The differential subcellular location of the BACE1
cleavage of APPSwe relative to APPWT provides an explanation
for the failure of PrPC deletion to affect A accumulation in
APPSwe,Ind mice. Thus, although PrPC exerts no control on
cleavage ofAPPSwe byBACE1, it has a profound influence on the
cleavage ofAPPWT, suggesting thatPrPCmaybe a keyprotective
player against sporadic Alzheimer disease.
A smallminority (1%) of Alzheimer disease (AD)2 cases are
inheritable and are caused by mutations in the genes encoding
the amyloid precursor protein (APP), presenilin-1 (PS1), and
PS2 (1). Specific examples include the Swedish familial ADdou-
ble point mutation K670N/M671L in APP (2) and the Indiana
familial AD point mutation V717F in APP (3). However, the
underlying causes remain elusive for the majority of late onset
sporadic AD cases. AD is characterized by the deposition in the
brain of amyloid plaques composed primarily of the 40–42-
amino acid amyloid- (A) peptide (4), which is derived from
APP through sequential proteolytic cleavage by the -secretase
(-site APP-cleaving enzyme-1 (BACE1)) and the PS1- or PS2-
containing -secretase complex (5). Cleavage of APP at the
Met671-Asp672 peptide bond by BACE1 is the first and rate-
limiting step in the production of A (6).
The activity of BACE1 is increased in the brain in sporadic
AD and correlates with increased A load (7, 8), suggesting a
deregulation of normal homeostatic controlmechanisms in the
disease. The activity of BACE1 is regulated by a number of
proteins (9), including the cellular prion protein (PrPC) (10).
PrPC inhibited the action of BACE1 toward human APPWT in
cellular models, and the level of endogenous murine A was
significantly increased in the brain of PrPC-null mice (10). Fol-
lowing this, we proposed that a normal function of PrPCmay be
to protect against AD (11). Consistent with this hypothesis is
the observation that the level of PrPC is decreased in the hip-
pocampus of sporadic, but not familial, AD subjects, indicating
that the reduced level of PrPC is a primary mechanism of dis-
ease and is not a secondary consequence of AD-associated
changes (12).
BACE1 is synthesized in the endoplasmic reticulum (ER) as
an immature but catalytically active zymogen of approximately
60 kDa with an N-terminal prodomain (amino acids 22–45).
Subsequent removal of the prodomain by furin-like convertases
in the trans-Golgi network (TGN) along with other post-trans-
lational modifications transforms BACE1 into the mature pro-
tein of approximately 70 kDa (13–16). Themature BACE1 traf-
fics from the TGN to the plasma membrane before being
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reinternalized into the endosomal pathway alongwithAPP. It is
within these acidic endosomal compartments that BACE1 pri-
marily acts on wild type APP (APPWT) (14, 17–19). In contrast
to APPWT, the -secretase cleavage of APP with the Swedish
mutation (APPSwe) occurs primarily within the secretory path-
way (20, 21).
In this study, we have extended our work on the role of PrPC
in regulating BACE1 activity by determining themolecular and
cellular mechanisms involved. We demonstrate that BACE1
coimmunoprecipitates with PrPC from murine and human
brain and by surface plasmon resonance that PrPC interacts
directly with the prodomain of BACE1. Site-directedmutagen-
esis revealed that Pro29 in the prodomain of BACE1 is critical
for this interaction. Furthermore, by immunofluorescence
microscopy and fluorescence-activated cell sorting (FACS), we
show that this interactionwith the prodomain-containing form
of BACE1 retains the secretase in the TGN and inhibits its
trafficking to the cell surface and endosomes. As our previous
data indicated that PrPC functions upstream of A production,
we also examined the effect of PrPC deletion on A production
and deposition in a transgenic mouse model expressing human
APP with the Swedish and Indiana familial mutations
(APPSwe,Ind). Although deletion of PrPC had no effect on amy-
loid deposition in these transgenic mice, in a cellular model, we
demonstrate that PrPC did not inhibit the activity of BACE1
toward APPSwe but did inhibit the activity of BACE1 toward
APPWT. As APPSwe is preferentially cleaved by BACE1 in the
TGN rather than in endosomes as for APPWT, this substrate-
specific differential subcellular site of action of BACE1 provides
a molecular explanation for the lack of effect of PrPC on A
production and deposition in the APPSwe,Ind transgenic mice.
EXPERIMENTAL PROCEDURES
Coimmunoprecipitation—Frozen human brain tissue was
obtained from the Medical Research Council London Neuro-
degenerative Diseases Brain Bank (Institute of Psychiatry,
King’s College London). All materials were obtained with
informed consent and approval of the relevant local ethics com-
mittees. All subsequent experiments were performed with the
approval of the Leeds (Central) Research Ethics Committee.
Human hippocampal brain tissue from a non-demented indi-
vidual (male; age, 57; cause of death, left ventricular failure;
post-mortem delay, 45 h) and 129/Ola wild typemice (22) (age,
5 weeks) were homogenized in 9 volumes of phosphate-buff-
ered saline (PBS; without Ca2 and Mg2), 0.5% (v/v) Nonidet
P-40, 0.5% (w/v) sodium deoxycholate, pH 7.4 in the presence
of Complete protease inhibitor mixture (Roche Applied Sci-
ence) using an electric homogenizer. Samples were centrifuged
at 14,000 g for 10 min, and the protein content of the result-
ant supernatant was quantified using bicinchoninic acid.
Mouse or human brain homogenate (300 g) was precleared
using 0.5% (w/v) protein G-Sepharose (Sigma) for 30 min at
room temperature. The protein G-Sepharose was pelleted by
centrifugation at 14,000  g for 20 s, and the supernatant was
incubated in the presence or absence of 0.1% (v/v) of the PrP-
specific antibody 6H4 (Prionics AG, Zurich, Switzerland) over-
night at 4 °C. Protein G-Sepharose (0.5% (w/v)) was added to
the samples and incubated for 1 h at room temperature. The
immunocomplexes were pelleted by centrifugation at
14,000  g for 20 s; washed three times with 10 mM potas-
sium acetate, 1.5 mM MgCl2, 75 mM sodium citrate; and sub-
jected to immunoblotting.
SDS-PAGE and Immunoblotting—Proteins were resolved by
SDS-PAGE using either 7–17% polyacrylamide gradient, 10%,
or 14.5% polyacrylamide gels and transferred to Immobilon P
polyvinylidene difluoride (PVDF) membrane (Amersham Bio-
sciences). The membrane was blocked by incubation for 1 h
with PBS containing 0.1% (v/v) Tween 20 and 5% (w/v) dried
milk powder. Antibody incubations were performed in PBS-
Tween 20 containing 2% (v/v) BSA. The following antibodies
were used. 3F4 and 6D11 (both Eurogentec Ltd., Southampton,
UK) and SAF32 (Cayman Chemical, Ann Arbor, MI) recognize
PrPC, 22C11 (Millipore Ltd., Livingston, UK) recognizes APP,
and AC-15 recognizes actin (Sigma). 1A9 raised against a neo-
epitope formedonwild type sAPP following cleavage ofAPP
and the antibody recognizing the neoepitope on Swedish
sAPP were kindly provided by Dr. I. Hussain (GlaxoSmith-
Kline, Harlow, UK). EE-17 (Sigma-Aldrich) recognizes residues
46–61 of BACE1. BACE-Cat1 raised against the BACE1 cata-
lytic domain was kindly provided by Dr. R. Vassar (23). Anti-
body against the prodomain of BACE1 (residues 26–45) was
from Merck Chemicals Ltd., and antibody against BACE2 was
from Abcam (Cambridge, UK). Antibodies against the A-de-
grading enzymes neprilysin (R&D Systems, Inc.) and insulin-
degrading enzyme (Abcam) and antibodies against the synaptic
markers synaptophysin (Synaptic Systems GmbH), PSD95
(Synaptic Systems GmbH), and drebrin (MBL International
Corp., Woburn, MA) were from the sources indicated. Anti-
body against the -secretase complex components nicastrin
was fromAbcam, and antibody against presenilin-1N-terminal
fragment was from Covance (Cambridge, UK). Horseradish
peroxidase (HRP)-conjugated secondary antibodies were used
at 1:4000 in the same buffer. Bound antibody was detected
using the enhanced chemiluminescence detection method
(Amersham Biosciences). Blots were stripped using 100 mM
glycine, pH 2.5 for 30 min, blocked by incubation for 1 h with
PBS containing 0.1% (v/v) Tween 20 and 5% (w/v) dried milk
powder, and reprobed using the anti-actin antibody as
described above. Anti-Fc-HRP was diluted in PBS-Tween 20.
BACE1 ELISA—96-well plates (BD Biosciences) were coated
overnight with murine recombinant PrP (rPrP) (Allprion AG,
Schlieren, Switzerland) (20 pmol/well; 5 g/ml). The plates
were washed with washing buffer (Dulbecco’s phosphate-buff-
ered saline (DPBS) containing 0.05% (v/v) Tween 20 and 0.02%
(w/v) sodium azide) before being blocked for 2 h in 3% (w/v)
BSA diluted inDPBS containing 0.02% (w/v) sodium azide. The
plates were then incubated with various concentrations (0–20
pmol) of recombinant BACE1-Fc (a kind gift from Dr. R.
Matico, GlaxoSmithKline, Collegeville, PA) or recombinant
Thy1-Fc (Alexis Biochemicals, Lausen, Switzerland) for 2 h.
Residual material was washed away, and the plate was incu-
bated with anti-Fc-HRP (1:5000) for 2 h. Bound protein was
detected using 3,3,5,5-tetramethylbenzidine reagent (Kirkeg-
aard&Perry Laboratories, Inc., Gaithersburg,MD) and allowed
to develop for 30min prior to the addition of 1 MH3PO4 to stop
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the reaction. The absorbance was then measured at 450 nm on
an Anthos plate reader.
Surface Plasmon Resonance—All reagents and systems used
in this technique were obtained from Amersham Biosciences.
Surface plasmon resonance was performed on Biacore 3000
system. A carboxymethyldextran chip (CM5) was primed with
running buffer (DPBS, 0.005%Tween 20) and normalized using
BIAnormalizing solution (70% (w/v) glycerol). rPrP (10 g/ml
in 10 mM sodium acetate, pH 4.5) was immobilized to the chip
at a rate of 5g/min for 7min to a level of 1500 resonance units
(RU) by amine coupling. Recombinant rBACE1-Fc and PD-
rBACE1 obtained from pepsin digestion of the rBACE1-Fc
(provided by Dr. R. Matico, GlaxoSmithKline, Collegeville, PA)
were diluted in running buffer to a range of concentrations
(0–10,000 nM) and passed over the sensor chip surface at a flow
rate of 40 l/min. Each cycle consisted of a 300-s analyte injec-
tion (association phase) followed by a 300-s dissociation phase.
Regeneration was not necessary, but a 300-s stabilization
period was applied. The data were analyzed using Biacore eval-
uation software (BIAevaluation 3.2RC1). Base lines were
adjusted to zero for all curves and double referenced by sub-
tracting a sensorgram of buffer injected over the rPrP surface
from the experimental sensorgrams to give the curves repre-
senting specific binding. Curves weremodeled assuming a sim-
ple 1:1 interaction to generate kinetic data. The 2 value was
below 5 RU2, indicating a good fit to the binding model.
Fluorometric BACE1 Activity Assay—Membrane fractions
(10 g) were diluted in 100 mM sodium acetate, pH 4.5, 40 mM
NaCl, 10% (v/v) glycerol, 0.2% CHAPS, 1 mM EDTA, protease
inhibitor mixture (P8340, Sigma-Aldrich). The samples were
incubated in the presence or absence of-secretase inhibitor IV
(Merck Chemicals Ltd.) for 30 min at 37 °C before addition of
the quenched fluorescence peptide based on the APPSwe
sequence (FAM-ISEVNLDAEFR-TAMRA where FAM is car-
boxyfluorescein and TAMRA is carboxytetramethylrhod-
amine; GlaxoSmithKline, Stevenage, UK) (5 M) in 100 mM
sodium acetate, pH 4.5, 0.06% Triton X-100. The fluorescence
was thenmeasured on a SynergyHTBio-Tek fluorometer using
KC4 software with excitation and emission wavelengths set to
485 and 585 nm, respectively.
Site-directed Mutagenesis and Stable Transfection—BACE1
mutants were generated from the template cDNA encoding
human BACE1 in pIREShyg using the QuikChange II XL site-
directed mutagenesis kit (Stratagene, Cambridge, UK) with the
following primers (Eurogentec Ltd.) (mutant bases are indi-
cated in bold): For L28Q/L30Q mutant, the sense primer was
5-GCATCCGGCAGCCCCAGCGCAGCGG-3, and the anti-
sense primer was 5-CCGCTGCGCTGGGGCTGCCGGA-
TGC-3. For P29G mutant, the sense primer was 5-GGCAT-
CCGGCTGGGCCTGCGCAGCGG-3, and the antisense
primer was 5-CCGCTGCGCAGGCCCAGCCGGATGCC-3.
For APPSwe, the sense primer was 5-CGGAGGAGATCTCT-
GAAGTGAATTTGGATGCAGAATTCCGA-3, and the
antisense primer was 5-TCGGAATTCTGCATCCAAATTC-
ACTTCAGAGATCTCCTCCG-3. The resultant constructs
were verified by DNA sequencing. cDNA encoding the human
BACE1 mutants, BACE2, and APPSwe in the expression vector
pIREShyg were introduced by electroporation into human
embryonic kidney (HEK) cells expressing murine PrPC (con-
taining the 3F4 epitope tag at amino acids 108–111) (24) in the
expression vector pIRESneo or into cells expressing pIRESneo
expression vector only as a control. Cells were selected using
150 g/ml hygromycin B. SH-SY5Y cells were stably trans-
fected with cDNA encoding BACE1 and PrPC as described pre-
viously (10).
Cell Culture—Human neuroblastoma (SH-SY5Y) and HEK
cells were cultured in Dulbecco’s modified Eagle’s medium
containing 4.5 g/liter glucose with 2 mM L-glutamine supple-
mentedwith 50 units/ml penicillin and 0.1mg/ml streptomycin
(Lonza) and 10% (v/v) fetal bovine serum (FBS) (Sigma-
Aldrich). Cellsweremaintained in a humid atmosphere at 37 °C
containing 5% (v/v) CO2 in air. All cell lineswere grown to 100%
confluence and washed twice in DPBS (without Ca2 and
Mg2) prior to a 24-h incubation inOpti-MEMandGlutaMAX
(Invitrogen). Medium was harvested and stored at 20 °C for
use in the A ELISA or concentrated to 200 l in a Vivaspin
20-ml concentrator (10,000 molecular weight cutoff mem-
brane) centrifuged at 1900 g for1 h in a bench top centri-
fugemaintained at 4 °C. For analysis of cell-associated proteins,
cells werewashed inDPBS, scraped, and pelleted at 1400 g for
3 min. Cells were lysed in 50 mM Tris/HCl, 150 mM NaCl, 0.5%
(w/v) sodium deoxycholate, 1% (v/v) Nonidet-P40, pH 8.0. For
the preparation of membranes, cells were resuspended in 3 ml
of 50mMHEPES, pH 7.5 and sonicated at an amplitude of 7m
for 30 s using a Soniprep150. The cell suspension was then
centrifuged at 2500  g for 10 min at 4 °C to pellet cell mem-
branes and nuclei. The supernatant was then centrifuged in a
Beckman Coulter Optima at 100,000 g for 1 h at 4 °C. Mem-
branes were resuspended in 50 mM Tris/HCl, pH 7.5, 2 mM
EDTA, 150 mM NaCl, 1% (w/v) CHAPSO.
siRNA Transfection—siRNAs corresponding to the human
PRNP gene were synthesized by Thermo Scientific Dharma-
con (Sussex, UK) as ON-TARGET plus SMARTpool. The
sequences of the siRNAs are as follows: UCACCGAGAC-
CGACGUUAA, GAUCGAGCAUGGUCCUCUU, AGAUGU-
GUAUCACCCAGUA, and GACCGUUACUAUCGUGAAA.
HEK293 cells were seeded at 60–70% confluence in a T80 flask
24 h before transfection. siRNA (1Mof the stock solution) was
mixed with the corresponding half-volume of Dharmafect 1
reagent in Opti-MEM (Invitrogen) for 20 min and applied to
the cells in a final volumemade up to 5ml with DMEM supple-
mented with 10% FBS. After incubation for 48 h at 37 °C, cells
were washed with PBS, and medium was conditioned for 24 h.
Immunofluorescence Microscopy—Cells grown on coverslips
were fixed with 4% (v/v) paraformaldehyde for 10min and then
permeabilized in DPBS containing 0.1% (v/v) Triton X-100 or
fixed and permeabilized in ice-cold 50% (v/v) methanol, 50%
(v/v) acetone for 10 min. Coverslips were incubated in DPBS
containing 5% (v/v) fish skin gelatin (Sigma-Aldrich) for 3–4 h
at room temperature before being incubated overnight at 4 °C
with the following primary antibodies: EE-17 against BACE1,
3F4 against PrPC, a mouse monoclonal antibody against early
endosomal antigen-1 (EEA1; BD Biosciences Pharmingen), a
sheep polyclonal antibody against the trans-Golgi network pro-
tein-46 (TGN-46; a kind gift from Dr. V. Ponnambalam, Uni-
versity of Leeds, Leeds, UK), and a chicken polyclonal antibody
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against calreticulin (Abcam). Finally, coverslips were incubated
with the appropriate fluorescent probe-conjugated secondary
antibodies (Jackson ImmunoResearch Laboratories Inc. and
Invitrogen) for 1 h and mounted on slides using Fluoro-
mount-G mounting medium (SouthernBiotech). Individual
cells were visualized using a DeltaVision Optical Restoration
Microscopy System (Applied Precision Inc.). Data were col-
lected from20 0.1-m-thick optical sections, and three-dimen-
sional data sets were deconvolved using the SoftWoRx program
(Applied Precision Inc.). Where indicated, the presented
images represent individual Z-slices. Colocalization of BACE1
with intracellular markers was performed using ImageJ.
FACS—SH-SY5Y cell suspensions were diluted to 5  106
cells/ml with DPBS containing 2.5 mM EDTA, pH 8 (DPBS/
EDTA buffer) and blocked for 20 min in 2% (v/v) fish skin gel-
atin diluted in DPBS/EDTA buffer. A 1 in 50 dilution of EE-17
was added to half the samples and incubated for 1 h. Following
this, cell suspensions were washed twice and centrifuged at
10,000 g for 5 min before being resuspended in 2% (v/v) fish
skin gelatin diluted in DPBS/EDTA buffer containing fluores-
cently conjugated secondary antibody (1:200) for 1 h. The cells
were then washed as described above and resuspended in
DPBS/EDTA buffer. Cells were sorted using a Partec PASIII
(Partec UK Ltd., Kent, UK), and data were analyzed usingWin-
MDI software version 2.9, or cells were sorted using a BD-LSR-
Fortessa (BD Biosciences), and data were analyzed using BD
FACSDiva software.
Transgenic Animals—Transgenic APPSwe,Ind mice overex-
pressing human APP with the Swedish (K670N/M671L) and
Indiana (V717F) familial AD mutations (line J20) (25) were
obtained from The Jackson Laboratory (Line B6.Cg-Tg(P-
DGFB-APPSwInd)20Lms/2J, stock number 006293) and The J.
David Gladstone Institutes (San Francisco, CA) and crossed
with inbred PrP knock-out mice (129Ola PrP/) (22). All the
transgenic mice used in this study were genotyped. DNA was
prepared from ear punch tissue using a DNeasy kit (Qiagen).
PCR was performed using the protocol specific for these mice
from The Jackson Laboratory. Brain hemispheres were either
frozen at80 °C for biochemical analysis or fixed in 10% formol
saline for histopathological analysis. Animal care was in accor-
dance with institutional guidelines.
Fixed brain tissue was processed, and tissue sections were
prepared as described (26). Paraffin sections (6 m) were
immunostained with a series of antibodies. The following anti-
bodies were used: 4G8 (1:100) monoclonal antibody raised
against A(17–24) (Abcam), A11 (1:1000) anti-prefibrillar olig-
omer polyclonal antibody (AB9234, Millipore, Watford, UK),
OC (1:5000) anti-fibrillar oligomer polyclonal antibody (a gift
from Professor C. Glabe, Department of Neurology, University
of California at Irvine School of Medicine, Irvine, CA), drebrin
(10 g/ml) monoclonal antibody to detect dendritic spines
(D029-3, MBL International Corp.), synaptophysin (Envision
kit K4001) polyclonal antibody to presynaptic vesicle protein
(N1566, Dako, Cambridgeshire, UK), anti-glial fibrillary acidic
protein (1:400) polyclonal antibody (Z0334, Dako), and Iba
(1:1000) polyclonal antibody, a microglial marker (01-1974,
Wako Chemicals USA, Inc.). Amyloid plaques were visualized
with 1% thioflavin S (Sigma).
Brain hemispheres were homogenized using a two-step
extraction protocol (27). Briefly, initial homogenization (120
mg/ml wet weight) was carried out using an electric homoge-
nizer in 2% (w/v) SDS containing protease mixture inhibitor
(Roche Diagnostics GmbH) followed by centrifugation at
100,000 g for 1 h at 4 °C. The resultant supernatant was col-
lected and analyzed using the A ELISA and SDS-PAGE fol-
lowedby immunoblotting. The pelletwas extracted in 70% (v/v)
formic acid in distilled H2O followed by centrifugation at
100,000 g for 1 h at 4 °C. The supernatant was collected and
analyzed using the A ELISA.
A ELISA—Sandwich ELISAs for the detection of human
A(1–40) and A(1–42) were performed as described previ-
ously (28). Briefly, 96-well microtiter plates were coated over-
night at 4 °Cwith primary antibodies against A(1–40) (33.1.1)
and A(1–42) (2.1.3.35.86) (kind gifts from C. & L. Eckman,
Mayo Clinic, Jacksonville, FL). Following blocking and incuba-
tion with conditioned medium, SDS-extracted brain homoge-
nate, or formic acid-extracted brain homogenate, bound A
peptides were detected with HRP-conjugated detection anti-
body (for A(1–40), 13.1.1-HRP (C. & L. Eckman); for A(1–
42), 4G8-HRP (Covance)).
Statistical Analysis—Densitometric analysis was performed
using the advanced image data analyzer (AIDA) program (Ray-
test Scientific Ltd.). The non-parametric two-tailed Mann-
WhitneyU test was used to compare two independent samples
when sample numbers were less than n  6. For sample num-
bers of n  6, the Kolmogorov-Smirnov test was used to test
that the data in each group were normally distributed. Follow-
ing this, Levene’s test was used to ensure that the data sets were
of equal variance. In samples where the data met the criteria of
a normal distribution and equal variance, the parametric inde-
pendent t test was used to calculate significance. p  0.05 was
considered significant (*, p  0.05; **, p  0.005; error bars,
	S.E.). The data were analyzed using the Statistical Package for
Social Sciences (SPSS 12.0.1) program (Chicago, IL).
RESULTS
PrPC directly interacts with the prodomain of BACE1. Previ-
ously, we reported that BACE1 coimmunoprecipitated with
PrPC in SH-SY5Y cells (10), although it remained to be estab-
lished whether this was due to a direct protein-protein interac-
tion. Initially, we extended this observation by examining
whether the two endogenous proteins interacted in the brain.
BACE1 coimmunoprecipitated with PrPC in both murine and
human brain (Fig. 1A), providing further evidence that the
interaction between the two proteins is physiological. Then, to
investigate whether this was a direct protein-protein interac-
tion, we utilized an ELISA system using recombinant proteins.
Recombinant human BACE1 with an Fc tag at the C terminus
(rBACE1-Fc; Fig. 1, B andC) bound specifically to immobilized
rPrP (Fig. 1D). In contrast to rBACE1-Fc, a control Fc-tagged
form of human Thy1 (rThy1-Fc) did not interact with the
immobilized rPrP to the same extent (7.4-fold less bound at the
highest concentration tested) (Fig. 1D), indicating that the PrP-
BACE1 interaction was specific. Next, we utilized surface plas-
mon resonance to interrogate further the interaction between
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PrPC and BACE1. rBACE1-Fc bound to the immobilized rPrP
in a dose-dependent manner with a Kd of 3.19 M (Fig. 1E).
The coimmunoprecipitation studies indicated that PrPC was
interacting with the lower molecular weight immature form of
BACE1 (Fig. 1A) (10). The rBACE1-Fc used in the above studies
contains the prodomain as evidenced by its reactivity to an anti-
body raised against residues 26–45 in the prodomain (Fig. 1, B
and C). Therefore, to determine whether PrPC was indeed
interacting with the prodomain of BACE1, we utilized a form of
BACE1 lacking the prodomain (PD-rBACE1) that migrated
on SDS-PAGE as a single band at 62 kDa and was no longer
recognized by the prodomain antibody (Fig. 1C). N-terminal
sequencing confirmed that PD-rBACE1 indeed lacked the
prodomain, beginning at residue 46. PD-rBACE1 displayed a
specific activity toward a quenched fluorescent peptide sub-
strate similar to that of the original prodomain containing
rBACE1-Fc (11.73 and 12.4 units/min/g of protein, respec-
tively), consistent with reports that the prodomain does not
inhibit the catalytic activity of the enzyme (15, 16). Using sur-
face plasmon resonance, PD-rBACE1 was observed not to
bind to the immobilized rPrP (Fig. 1F). Together, these data
indicate that the N-terminal prodomain of BACE1 (residues
22–45) is required for the direct interaction between BACE1
and PrPC.
Pro29 in Prodomain of BACE1 Is Critical for Interaction with
PrPC—To gain further insight into the direct interaction
betweenBACE1 andPrPC,we investigatedwhether PrPCwould
inhibit the action of the homolog of BACE1, BACE2. BACE2
shares 45% sequence identity with BACE1 and also cleaves APP
albeit at the Phe19-Phe20 bond in the A sequence (29, 30).
Upon coexpression in HEK293 cells, PrPC significantly inhib-
ited the action of BACE2 on APPWT (Fig. 2, A and B). As PrPC
inhibits both BACE1 and BACE2, we identified a conserved
sequence (LPLR) in the prodomains of both proteins (Fig. 2C)
that we interrogated in BACE1 by site-directed mutagenesis.
L28Q/L30Q and P29G mutants were coexpressed in HEK293
cells with PrPC. The P29Gmutant was expressed at a level sim-
ilar to that of the wild type BACE1 with the majority being
complex glycosylated and appearing as the 75-kDamature form
(Fig. 2D), whereas the L28Q/L30Q mutant was predominantly
(90%) expressed as the 65-kDa immature ER form (Fig. 2D).
The P29Gmutant had an activity toward the quenched fluores-
cent peptide substrate similar to that of wild type BACE1 (Fig.
2E). As the L28Q/L30Q mutant did not appear to traffic
through the secretory pathway correctly being present mainly
as the immature ER form (Fig. 2F) and did not efficiently fold
into a fully catalytically active form (Fig. 2E), it was not studied
further. The prodomain containing a complex glycosylated
immature form of BACE1 (75 kDa) was increased in the pres-
ence of PrPC in the wild type BACE1-expressing cells but not in
the P29G-expressing cells (Fig. 2, F and G). In the wild type
FIGURE 1. PrP directly interacts with prodomain of BACE1. A, brain homo-
genates from 129/Ola wild type mice and a non-demented individual were
immunoprecipitated in the presence (IP) or absence (Control) of 6H4, and the
immunoprecipitates were subjected to SDS-PAGE and immunoblotting
alongside total brain homogenate (Input) with antibody SAF32 for murine
and 3F4 for human PrPC and antibody EE-17 for BACE1. B, schematic of the
prodomain-containing (rBACE1-Fc) and prodomain-lacking (PD-rBACE1)
BACE1 showing the epitopes recognized by antibody EE-17 and the prodo-
main antibody (pro-BACE1). C, rBACE1-Fc (lane 1) and PD-rBACE1 (lane 2)
immunoblottedwith EE-17, prodomain antibody (pro-BACE1), or anti-Fc-HRP.
D, rPrP was immobilized and incubated with rBACE1-Fc or rThy1-Fc before
detection with anti-Fc-HRP (n 3). E, rPrP was immobilized onto the surface
of a CM5 sensor chip, and rBACE1-Fc was passed over the surface.
The response from the reference was subtracted, and the base lines were
adjusted to zero to give response over time binding curves. F, rBACE1-Fc
(2500 nM) andPD-rBACE1 (2500 nM)were passed over the rPrP-immobilized
sensor chip. Error bars,	S.E.
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BACE1-expressing cells, coexpression of PrPC significantly
reduced the amount of sAPP in the conditioned medium
derived from the endogenous human APPWT, whereas PrPC
failed to inhibit the amount of sAPP secreted from the P29G-
expressing cells (Fig. 2, H and I). These data indicate that PrPC
is interacting with the prodomain of BACE1 and that Pro29 is
critical for this interaction. Furthermore, these observations
suggest that this interaction with PrPC prevents the removal of
the prodomain, thus influencing the proportion of BACE1 that
is cleaved to generate the mature form.
PrPC Alters Subcellular Localization of BACE1—Next, we
investigated whether this interaction between PrPC and the
prodomain of BACE1 altered the subcellular location of BACE1
by assessing whether the colocalization of BACE1 with various
subcellular markers was altered by PrPC. In SH-SY5Y cells,
immunofluorescence microscopy revealed that PrPC caused a
significant reduction (28.9	 4.7%, p 0.025) in the colocaliza-
tion of BACE1with the early endosomalmarker EEA1 (Fig. 3,A
and B) and as assessed by FACS reduced the amount of BACE1
at the cell surface by 28.2	 9.1% (p 0.015) (Fig. 3, C and D).
FIGURE 2. Identificationof binding site for PrP inBACE1prodomain.A, lysates fromHEK293 cells expressing BACE2 in thepresence or absence or PrPCwere
subjected toSDS-PAGEand immunoblotting todetectAPPWT, BACE2, PrP
C, andactin.Mediumsampleswereblotted for sAPP.B, quantificationofmultiple sAPP
blots fromHEK cells expressing BACE2 (n 3). C, sequence alignment of the prodomains of BACE1 and BACE2. The LPLR conserved region is boxed.D, lysates
from HEK293 cells expressing either L28Q/L30Q BACE1, WT BACE1, or P29G BACE1 in the presence or absence of PrPC were subjected to SDS-PAGE and
immunoblotting to detect total BACE1, PrPC, APP, and actin. E, BACE1 activity toward the synthetic peptide substrate inmembranes from theHEK293 cells. The
percentage of activity of themutants was calculated relative toWT BACE1. F, amount of immature BACE1 (detected with the prodomain-specific antibody) in
membranes.G, quantification by densitometric analysis ofmultiple immunoblots of the immature TGN form of BACE1 in the presence or absence of PrPC (n
5). H, amount of sAPP in the conditioned medium. I, ratio of sAPP relative to total BACE1 for the WT BACE1- and P29G-expressing cells in the absence or
presence of PrPC (n 3). *, p 0.05; n.s., not significant; error bars,	S.E.
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As both the cell surface and endosomal localization of BACE1
was reduced in the presence of PrPC, we investigated whether
PrPC was retaining BACE1 within the secretory pathway.
Immunofluorescence microscopy revealed that PrPC signifi-
cantly increased (29.4	 7.6%, p 0.028) the colocalization of
BACE1with the TGN-specific protein TGN-46 (Fig. 3, E and F)
FIGURE 3. PrPC alters subcellular localization of BACE1. A, BACE1 and EEA1 staining of SH-SY5Y cells expressing BACE1 in the presence or absence of PrPC.
B, ImageJ analysis of BACE1 and EEA1 colocalization in SH-SY5Y cells in the presence or absence of PrPC. The percentage of colocalization was calculated over
13 images. C, BACE1 cell surface fluorescence in the presence or absence of PrPC determined by FACS analysis. D, quantitation from FACS analysis of BACE1
surface fluorescence in the presence or absence of PrPC (n 9). E, BACE1 and TGN staining in the presence or absence of PrPC. F, ImageJ analysis of BACE1 and
TGN-46 colocalization in SH-SY5Y cells in the presence or absence of PrPC. The percentage of colocalization was calculated over 13 images. G, BACE1 and
calreticulin staining in the presence or absence of PrPC.H, ImageJ analysis of BACE1 and calreticulin colocalization in SH-SY5Y cells in the presence or absence
of PrPC. The percentage of colocalization was calculated over 12 images. Scale bar, 10 m. *, p 0.05; n.s., not significant; error bars,	S.E.
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but did not alter the amount of BACE1 colocalized with the ER
marker calreticulin (Fig. 3, G and H). Together, these results
indicate that the interaction of PrPC with the prodomain of
BACE1 slows its trafficking following its exit from the ER,
increasing its localization in the TGN and thereby reducing the
amount at the cell surface and in endosomes.
To confirm that the above results were not caused by forced
interactions due to overexpression of the proteins, we used
FACS analysis to determine the surface level of endogenous
BACE1 inHEK293 cells following siRNAknockdown of endog-
enous PrPC (Fig. 4A). Knockdown of endogenous PrPC (Fig. 4B)
resulted in a 151% increase in the amount of endogenous
BACE1 at the cell surface (Fig. 4, C and D). Together with the
coimmunoprecipitation experiments of endogenous proteins
in brain (Fig. 1A), these results indicate that the interaction
between BACE1 and PrPC is of physiological relevance and has
a physiological effect.
Deletion of PrPC Does Not Affect APP Processing or ADepo-
sition in Mouse Model—We extended our analysis of PrPC
function in AD by examining the effect of PrPC deletion on A
production and deposition in a transgenic mouse model
expressing human APP. PrPC-null 129/Ola mice (22) were
crossed withmice expressing humanAPPwith APPSwe,Ind (25).
Immunoblot analysis confirmed the lack of PrPC in the
APPSwe,Ind/PrP/mice (Fig. 5, A and B); however, PrPC dele-
tion had no effect on the level of sAPPSwe (Fig. 5, A and B).
Histopathological analysis indicated that therewas no apparent
difference in thioflavin S fluorescence (Fig. 5C) or in total A
plaque load (Fig. 5D) in the hippocampus between the
APPSwe,Ind/PrP/ mice and the APPSwe,Ind/PrP/ mice. As
oligomeric forms of A more closely correlate with cognitive
dysfunction than A plaque load (31), we investigated whether
depletion of PrPC affected the level of prefibrillar A oligomers
using theA11 antibody (32) and fibrillarA oligomers using the
OCantibody (33).However, no apparent differences in the level
of prefibrillar A oligomers detected with the A11 antibody
(Fig. 5E) or in fibrillar A oligomers detected with the OC anti-
body (Fig. 5F) were observed between the APPSwe,Ind/PrP/
and the APPSwe,Ind/PrP/mice. Further analysis revealed that
there was no difference in the amount of soluble (SDS-ex-
tracted) A(1–40) and A(1–42) (Fig. 5G) in the APPSwe,Ind/
PrP/ mice compared with the APPSwe,Ind/PrP/ mice at
either 20 or 40 weeks of age. There were small but significant
increases in the amount of insoluble (formic acid-extracted)
A(1–40) at 40 weeks (Fig. 5H) and in the amount of insoluble
A(1–42) at both 20 and 40 weeks (Fig. 5H) in the APPSwe,Ind/
PrP/mice compared with the APPSwe,Ind/PrP/mice. Fur-
thermore, deletion of PrPC had no apparent effect on the syn-
aptic immunoreactivity of synaptophysin or drebrin or on
microglial or astrocyte activation in the hippocampus (supple-
mental Fig. S1, A–D). In addition, immunoblot analysis
revealed that there was no significant difference in the levels of
the synaptic proteins synaptophysin, PSD95, and drebrin in the
APPSwe,Ind/PrP/ mice compared with the APPSwe,Ind/
PrP/mice (supplemental Fig. S1, E and F). Also, there was no
difference in the level of the -secretase complex components
presenilin-1 and nicastrin in the APPSwe,Ind/PrP/mice com-
pared with the APPSwe,Ind/PrP/mice (supplemental Fig. S1,
E and F). Finally, we investigated whether the lack of effect of
PrPC depletion on A deposition was due to an increase in A
degradation by examining the levels of the A-degrading
enzymes neprilysin and insulin-degrading enzyme. However,
no significant difference in the levels of these two enzymes was
observed between the APPSwe,Ind/PrP/ and the APPSwe,Ind/
PrP/mice (supplemental Fig. S1, E and F), indicating that the
lack of effect of PrPC deletion on A deposition was unlikely
due to an increase in A degradation. Taken together, these
extensive biochemical and histopathological analyses indicate
that deletion of PrPC does notmodulate the deposition of A in
this APPSwe,Ind transgenic mouse model.
FIGURE 4. siRNA knockdown of endogenous PrPC increases cell surface
localization of BACE1. A, siRNA knockdown of endogenous PrPC in HEK293
cells. Lysates were subjected to SDS-PAGE and immunoblotting to detect
endogenous APP, PrPC, and actin. B, endogenous BACE1 cell surface fluores-
cence in the presence and after knockdown of endogenous PrPC as deter-
mined by FACS analysis. C, quantitation from FACS analysis of BACE1 surface
fluorescence following siRNA knockdown of PrPC (n  9). *, p  0.05; error
bars,	S.E.
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PrPC Differentially AffectsMetabolism of APPWT andAPPSwe—
Our previous observations showed that PrPC inhibited the
activity of BACE1 toward humanAPPWT in cellularmodels and
toward murine APPWT in PrP-null mice (10). To reconcile
these observations with the lack of effect of deletion of PrPC on
A production and deposition in the APPSwe,Ind transgenic
mice, we considered whether this was due to the Swedish dou-
ble point mutation K670N/M671L N-terminal to the BACE1
cleavage site. To investigate this, the effect of PrPC on A pro-
duction was examined in HEK293 cells stably expressing either
APPWT (Fig. 6A) or APPSwe (Fig. 6B). PrPC dramatically
reduced the secretion of A(1–40) and A(1–42) from the
FIGURE5.PrPCdeletiondoesnotaffectAPPprocessingorAdeposition in transgenicmousemodel.Brainhemispheres from20-and40-weekAPPSwe,Ind/
PrP/ (WT/WT) andAPPSwe,Ind/PrP
/ (Null/Null)micewerehomogenizedusing a two-stepprotocol, and the SDS-soluble fractionwas subjected to SDS-PAGE
and immunoblotting. A, representative blots of PrPC, APP, sAPPSwe, and BACE1 with actin as a loading control. B, relative amounts of protein determined by
densitometric analysis (n  6). C–F, histological analysis of the cerebrum of APPSwe,Ind/PrP
/ (WT/WT) and APPSwe,Ind/PrP
/ (Null/Null) mice showing A
amyloid deposits. C, thioflavin S fluorescent aggregates. D, A-immunoreactive aggregates detected with antibody 4G8. E, A oligomeric deposits (arrows)
detected with antibody A11. F, A oligomeric deposits detected with antibody OC. Scale bars, 400 m in C and D, 100 m in E, and 200 m in F. Soluble
(SDS-extracted) A(1–40) and A(1–42) (G) and insoluble (formic acid-extracted) A(1–40) and A(1–42) (H) detected by ELISA (n 7–9) are shown. *, p
0.05; **, p 0.005; error bars,	S.E.
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cells expressing APPWT (Fig. 6C), consistent with our previous
data in other cell lines (10). However, there was no inhibitory
effect of PrPC on the secretion of the A peptides from the cells
expressing APPSwe (Fig. 6D). To confirm this result, we per-
formed the converse experiment using siRNA to knock down
the endogenous PrPC in the HEK293 cells expressing either
APPWT (Fig. 6E) or APPSwe (Fig. 6F). Knockdown of PrPC
resulted in an increase in sAPP in the cells expressing APPWT
(Fig. 6G) but had no effect in the cells expressing APPSwe (Fig.
6H). These data clearly show that PrPC differentially affects the
activity of BACE1 toward APPWT and APPSwe.
DISCUSSION
We have reported previously that PrPC inhibits the BACE1
cleavage of APPWT and that deletion of PrPC in both cell and
animal model systems resulted in an increase in endogenous
A levels (10). From this, we proposed that a normal function of
PrPC may be to regulate the production of the neurotoxic A
and therefore to protect against AD (11). In the present study,
we have extended these observations by determining the
molecular and cellular mechanisms involved in the regulation
of BACE1 by PrPC. Here, we show that PrPC interacts directly
with the prodomain of the immature, Golgi-localized form of
BACE1 and that Pro29 in the prodomain is critical for this
interaction.
Prodomain cleavage, which occurs in the TGN by furin-like
convertases, is required for the generation of mature BACE1
(13–16). The mature BACE1 is present at the cell surface from
where it is internalized into endosomes where it preferentially
cleaves APPWT (6). Our data show that PrPC interacts with the
prodomain of BACE1 and that Pro29 in the prodomain appears
to be critical for this protein-protein interaction. This interac-
tion of PrPC with the immature prodomain-containing form of
BACE1 results in an increased proportion of the secretase in the
TGN with a subsequent reduction in the amount at the cell
surface and in endosomes. We propose that this retention of
BACE1 in the secretory pathway provides a mechanism to
explain the inhibitory effect of PrPC on the amyloidogenic pro-
cessing of APPWT, which is cleaved by BACE1 in endosomes
(14, 17–19). Although there is only an approximately 30%
reduction in BACE1 localization to the endosomes, this is
enough to nearly abolish the generation of A. It is unlikely that
the total cellular pool of BACE1 is intended for localization to
the appropriate subcellular compartments for processing of
APPWT as BACE1 is required for the processing of several other
substrates (34).
The mechanism of action of PrPC on BACE1 processing of
APP is reminiscent of that of the sorting protein-related recep-
tor, which also inhibits the proteolytic processing of APP and
production of A (35). Like PrPC, sorting protein-related
receptor coimmunoprecipitated only with the smaller prodo-
main-containing immature form of BACE1, suggesting an
interaction in the Golgi (36). However, unlike sorting protein-
related receptor, which also interacts with APP, impairing its
transport through the Golgi and blocking access of APP to
BACE1 (35, 36), PrPC does not interact with APP (10).
We also sought to confirm a role for PrPC upstream of A
production by examining the effect of deletion of PrPC in a
transgenic mouse model expressing mutant human APP. For
this purpose, we chose the widely used J20 transgenic mouse
model, which expresses humanAPPwith the Swedish and Indi-
ana mutations under the control of the platelet-derived growth
factor (PDGF) promoter (25). Surprisingly, despite extensive
biochemical and histopathological analysis, we could find no
evidence for an affect of PrPC deletion on APP proteolytic pro-
cessing, A plaque deposition, or levels of soluble A or A
FIGURE 6. PrPC does not inhibit production of A from cells expressing
APPSwe. Lysates from HEK293 cells expressing either APPWT (A) or APPSwe (B)
in the presence or absence or PrPC were subjected to SDS-PAGE and immu-
noblotting to detect PrPC, APP, and actin.Medium fromHEK293 cells express-
ing either APPWT (n 3) (C) or APPSwe (n 6) (D) in thepresenceor absenceor
PrPC was subjected to ELISA to detect A(1–40) and A(1–42). Lysates from
HEK293 cells expressing either APPWT (E) or APPSwe (F) in which endogenous
PrPC had been knocked down by siRNA were subjected to SDS-PAGE and
immunoblotting to detect APP, endogenous PrPC, and actin. Medium sam-
ples were blotted for sAPP. Quantification by densitometric analysis ofmul-
tiple immunoblots of sAPP from APPWT (G) or APPSwe (H) in the presence or
absence of PRNP siRNA (n 4) is shown. *, p 0.05; n.s., not significant; error
bars,	S.E.
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oligomers. Consistent with our observations in the APPSwe,Ind
(J20) transgenic mice, it has also been reported recently that
deletion of PrPC failed to alter BACE1 processing of APP, A
levels, and A deposition in the APPSwe/PS1E9 (37) and the
APPSwePS1L166P (38) transgenic models and previously that
overexpression of PrPC in APPSwe,Ind transgenic mice resulted
in only a minor increase in A plaque formation but no signif-
icant change in A(1–40) or A(1–42) (39). However, consid-
ering that APPWT is primarily cleaved by BACE1 in endosomes
(17–19), whereas the cleavage of APPSwe occurs primarily
within the TGN (20, 21), our current data indicating that PrPC
interacts directly with the prodomain of BACE1, retaining
BACE1 in the TGN and decreasing its amount in endosomes,
provide a cellularmechanism to explain the differential effect of
PrPC on APPWT and APPSwe metabolism (Fig. 7). Thus, the
differential subcellular sites of action of BACE1 on APPWT (in
endosomes) compared with APPSwe (in the TGN) can explain
the lack of effect of PrPC deletion on APP processing and A
deposition in the APPSwe,Ind/PrP/ mice. The dramatically
different effect of PrPC on the BACE1 cleavage of APPWT and
APPSwe in HEK cells confirms this.
Clearly, animal models based on the rare familial AD muta-
tions in APP have played a major role in defining disease-re-
lated mechanisms and in evaluating novel therapeutic
approaches (1). However, a recent report highlighted the
potential limitation of such models when the decreased
potency of BACE1 inhibitors in cells and mice expressing
APPSwe was shown to be due to the different subcellular loca-
tion of APPSwe processing by BACE1 (40), similar to our obser-
vations here on the differential effect of PrPCon themetabolism
of APPWT and APPSwe by BACE1. Consistent with our hypoth-
esis that PrPC regulates themetabolism of APPWT is the finding
that PrPC is decreased in the hippocampus and temporal cortex
in sporadic AD but not in familial AD, indicating that the
reduction in PrPCwould appear to reflect a primarymechanism
of disease and is not merely a secondary consequence of other
AD-associated changes (12). Although PrPC exerts no control
on cleavage of APPSwe that is associated with familial AD, it has
a profound influence on the cleavage of APPWT, and together
with other data (12), this suggests that PrPC may be a key pro-
tective player against sporadic AD.
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